Research area
Tissue repair and recovery
Compounds studied for wound healing, tissue repair, and recovery from injury, spanning published animal research through widely circulated but largely unstudied community use.
16 entries in this category.
-
Ac-SDKP
Ac-SDKP (goralatide) is a natural, ACE-regulated tetrapeptide studied almost exclusively in animal models for reducing cardiac, renal, pulmonary, and hepatic fibrosis; no human clinical dosing trials of the peptide itself were identified.
-
ARA-290
ARA-290 (cibinetide) is a non-hematopoietic, erythropoietin-derived peptide studied in Phase 2 human trials for sarcoidosis-associated small fiber neuropathy and diabetic neuropathy; investigational, with FDA orphan drug and fast track status but no approval.
-
BPC-157
BPC-157 is a synthetic fifteen amino acid peptide with no identified receptor after more than thirty years of study. About 77 percent of its 230 published papers come from one laboratory in Zagreb, and all three published human reports come from one clinic in Florida, totalling thirty-one patients with no control group.
-
FLGR242
FLGR242 is a seller-named follistatin construct with no published study. What the patent, the follistatin literature and the registries show.
* Also filed under: Growth hormone axis
-
Follistatin 344
Also relevant to tissue repair and recovery research. Follistatin 344 is a myostatin-binding protein isoform studied mainly through AAV gene-therapy trials for muscular dystrophy, not as the injected protein sold under this name by research-chemical vendors, which has no human safety or dosing data.
* Also filed under: Growth hormone axis
-
GHK-Cu
GHK-Cu is a copper-bound three amino acid peptide used mainly in skincare. It is the only compound on this site with a real randomised placebo-controlled human trial, and that trial found it no better than placebo. Every positive human claim traces to conference abstracts, a defunct journal, a book chapter or a press release.
-
GHK-Cu / BPC-157
GHK-Cu / BPC-157 is the two-peptide subset of GLOW, usually 50 mg GHK-Cu to 10 mg BPC-157. No study has tested the pair together, but BPC-157's sequence happens to contain none of the amino acids copper oxidation chemistry usually targets, which is one genuine thing this specific pairing has going for it that a stability study still has not confirmed.
-
GLOW
GLOW is a vendor name for GHK-Cu, BPC-157 and TB-500 in one vial, usually 70 mg total with GHK-Cu at about 71 percent of it. It is KLOW without the KPV, no study has tested the three together, and the composition varies between suppliers.
-
KLOW
KLOW is a vendor name for GHK-Cu, KPV, BPC-157 and TB-500 in one vial, usually 80 mg total with GHK-Cu at roughly 62 percent of it. No study has tested the four together, and nobody has published on what the copper in GHK-Cu does to the other three peptides in solution.
-
KPV
Also relevant to sexual health and melanocortin research. KPV is a three amino acid fragment of alpha-MSH with anti-inflammatory activity in cell culture and in mice. No human trial of it has ever been published or registered, and the FDA said the same in its own 2026 review.
* Also filed under: Sexual health and melanocortin
-
Larazotide
Larazotide acetate (AT-1001) is a zonulin-antagonist peptide studied through Phase 3 for celiac disease; its 2022 Phase 3 trial was stopped for futility, so it remains unapproved.
-
LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, studied for its membrane-disrupting antibacterial action and role in wound healing and immune signaling; no human dosing trials exist and a CAS-number conflict affects sourcing.
-
TB-500
TB-500 is a synthetic seven amino acid fragment, not thymosin beta-4, which is a 43 amino acid protein with a real clinical record. No human study of TB-500 has ever been conducted, its flagship preclinical result used a different molecule, and product testing by racing authorities found many vials contain no peptide at all.
-
TB-500 Fragment (17-23)
TB-500 Fragment (17-23), or Ac-LKKTETQ, is the actin-binding segment of thymosin beta-4, a distinct, far less-studied molecule from the full-length Tβ4 that most vendor "TB-500" products actually are.
-
Thymosin Beta-4
Thymosin beta-4 is the endogenous 43-amino-acid, actin-binding protein behind RegeneRx's RGN-259, RGN-352 and RGN-137 clinical programs for dry eye, wound healing and epithelial repair. It is not the same molecule as "TB-500," a separately characterized, N-acetylated seven-amino-acid fragment that FDA assigns its own chemical identity, and that no human study has ever tested under that name.
-
Wolverine
Wolverine is a vendor name for BPC-157 and TB-500 in one vial, at ratios that vary by supplier. The single study that tested the combination in an animal found it no better than TB-500 alone, and no clinical trial of it exists.